Stephens Investment Management Group LLC Has $12.84 Million Holdings in BioLife Solutions, Inc. $BLFS

Stephens Investment Management Group LLC boosted its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 10.9% during the 1st quarter, HoldingsChannel reports. The firm owned 673,129 shares of the medical equipment provider’s stock after buying an additional 66,242 shares during the quarter. Stephens Investment Management Group LLC’s holdings in BioLife Solutions were worth $12,843,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Tudor Investment Corp ET AL lifted its position in BioLife Solutions by 85.2% in the 3rd quarter. Tudor Investment Corp ET AL now owns 111,356 shares of the medical equipment provider’s stock worth $2,841,000 after buying an additional 51,217 shares in the last quarter. Summit Creek Advisors LLC grew its position in BioLife Solutions by 24.2% in the fourth quarter. Summit Creek Advisors LLC now owns 238,802 shares of the medical equipment provider’s stock worth $5,774,000 after acquiring an additional 46,541 shares in the last quarter. Capricorn Fund Managers Ltd bought a new stake in BioLife Solutions in the fourth quarter worth $9,153,000. Vanguard Group Inc. increased its holdings in shares of BioLife Solutions by 4.0% during the 4th quarter. Vanguard Group Inc. now owns 3,087,386 shares of the medical equipment provider’s stock valued at $74,653,000 after acquiring an additional 119,868 shares during the last quarter. Finally, Granahan Investment Management LLC raised its position in shares of BioLife Solutions by 23.0% in the fourth quarter. Granahan Investment Management LLC now owns 482,356 shares of the medical equipment provider’s stock valued at $11,663,000 after purchasing an additional 90,260 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Stock Performance

BLFS opened at $28.11 on Monday. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -351.33 and a beta of 1.94. The firm’s 50-day simple moving average is $24.66 and its 200-day simple moving average is $23.10. BioLife Solutions, Inc. has a twelve month low of $17.86 and a twelve month high of $30.00.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.03. The company had revenue of $27.50 million during the quarter, compared to analyst estimates of $25.66 million. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. As a group, sell-side analysts anticipate that BioLife Solutions, Inc. will post 0.02 EPS for the current fiscal year.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $23.70, for a total value of $15,405,000.00. Following the completion of the sale, the insider owned 4,757,165 shares in the company, valued at approximately $112,744,810.50. This trade represents a 12.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders have sold 1,200,000 shares of company stock worth $28,125,000. 2.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BLFS shares. Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Monday, April 20th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $32.00.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.